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specific labeled protein 
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Thomas 
 
MR Imaging of Pacing Induced Ventricular Dyssynchrony in an Isolated Human Heart 
Michael D. Eggen, Michael G. Bateman, Christopher D. Rolfes, Stephen A. Howard, Cory M. Swingen, Paul A. Iaizzo 
 
GADD45γ is a Novel Downstream Target of MyoD and Negatively Regulates Survival and Self-Renewal of Muscle 
Stem Cells. 
Christopher Tastad, Hiroyuki Hirai, and Atsushi Asakura 
 
Structural Dynamics of Cardiac Calcium Regulation 
Kurt D. Torgersen, Christine B. Karim, Edmund Howard and David D. Thomas 
 
Prevention of dilated cardiomyopathy by chronic infusion of the membrane sealant Poloxamer 188 in canines with 
muscular dystrophy 
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by Solid-State NMR Spectroscopy 
Nathaniel J Traaseth, Raffaello Verardi, Lei Shi, Martin Gustavsson and Gianluigi Veglia 
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Gene transfer of engineered cardiac troponin C for modulation of myofilament Ca2+ sensitivity 
Lin Yang, Jen Davis and Joseph M. Metzger 
 
Structural dynamics of the myosin relay helix resolved by DEER and time-
resolved FRET 
 
Roman Agafonov, Sarah Blakely, Igor V. Negrashov, Margaret A. Titus, David D. Thomas, 
Yuri E. Nesmelov 
University of Minnesota, Minneapolis, Minnesota, USA 
 
We have used DEER (double electron-electron resonance) and TR-FRET (time-resolved 
fluorescence resonance energy transfer) to detect structural transitions within the myosin II 
relay helix. Major structural changes during the myosin II ATPase cycle take place in the 
force-generating domain. Crystal structures show that the converter domain, the relay helix, 
and SH1 helix have different conformations in the proposed pre- and post- powerstroke 
structural states of myosin. In the present study, we focus on the relay helix as a crucial 
structural element involved in coupling between the force-generating domain and the 
nucleotide-binding pocket. Cysteine mutations were introduced into a Cys-lite construct of 
Dictyostelium discoideum (Dicty) myosin in the lower 50k domain and the C-terminal end of 
the relay helix. These constructs were selectively modified with MSL/MSL or 
IAEDANS/DABCYL pairs, and the distance between probes was measured (a) in different 
myosin conformations trapped with nucleotides or nucleotide analogs and (b) after rapid 
mixing of myosin with ATP. In the latter experiment, designated transient time-resolved FRET, 
(TR)2FRET, we use a novel instrument that can acquire a complete subnanosecond time-
resolved fluorescence decay 10,000 times per second, during the transient phase of the 
ATPase reaction. Two conformations of the relay helix (with distinct probe-to-probe distances, 
presumably corresponding to the straight and bent states of the helix) were resolved. 
Observed distances were in good agreement with existing crystal structures, but at least two 
distinct structural states were present in certain biochemical states. The mole fraction of the 
“bent” conformation was higher with post-hydrolysis analogs (ADP.Vi, ADP.AlF4) bound at the 
active site. Kinetic experiments identified the same conformational states and showed a 
transition from the straight state of the helix to the bent state upon addition of ATP, allowing 
us to determine the rate of the conformational change within the helix. Our results reveal time-
resolved rearrangements within a single subdomain of myosin and provide insights into the 
coupling between binding of ATP and structural changes in the force-generating region. 
 
Cerebellar dysfunction and glutamatergic deficits in murine models of 
spinocerebellar ataxia type 5 (SCA5) 
 
Karen Armbrust1,2, Xinming Wang3, Takashi Obu1,2, Timothy Ebner3, Laura Ranum1,2 
(1) Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN. 
(2) Institute of Human Genetics, University of Minnesota, Minneapolis, MN. 
(3) Neuroscience, University of Minnesota, Minneapolis, MN. 
 
The spectrin repeat is a characteristic triple-alpha-helical bundle found in cytoskeletal proteins 
such as dystrophin, utrophin, and spectrin. Two mutations that produce in-frame deletions 
within the third spectrin repeat of beta-III spectrin cause spinocerebellar ataxia type 5 (SCA5), 
a slowly progressive, autosomal dominant neurodegenerative disease that primarily affects 
the cerebellum. Analysis of human SCA5 cerebellar autopsy tissue shows that the glutamate 
transporter EAAT4 and the glutamate receptor GluRδ2 fractionate abnormally, which 
suggests that SCA5 pathogenesis may involve abnormal glutamatergic neurotransmission 
and excitotoxic changes. To test this hypothesis and to elucidate other potential mechanisms 
of disease pathogenesis we have developed two transgenic murine models of SCA5 which 
express mutant beta-III spectrin in cerebellar Purkinje cells. Behavioral studies with a 
3xFLAG-tagged SCA5 murine model and a second conditional murine model that drives 
expression of untagged beta-III spectrin show that overexpressing mutant beta-III spectrin in 
cerebellar Purkinje cells causes cerebellar dysfunction. Histologic analysis of the 3xFLAG-
tagged SCA5 murine model shows that the SCA5 mutation alters the Purkinje cell distribution 
of the mutant β-III spectrin protein itself. Further studies with the conditional tet-regulated 
mice show that overexpression of untagged mutant beta-III spectrin alters the localization of 
the glutamate transporter EAAT4 and the metabotropic glutamate receptor mGluR1α and 
produces a concomitant deficit in mGluR1 function. These findings suggest that abnormalities 
in perisynaptic glutamatergic transmission may contribute to SCA5 pathogenesis. 
 
Functional Studies for MASH Gene Family in Muscle Stem Cells 
 
Ronneil Aviles, Atsushi Asakura, 
Department of Neurology 
 
Duchenne Muscular Dystrophy (DMD) is a disorder in which absence of the protein 
dystrophin results in decreasing muscle mass and progressive loss of muscle function. It is 
possible that muscle satellite cells, stem cells for skeletal muscle, transplanted into DMD 
patients will have the potential to replace these damaged tissues. The satellite cells are found 
in skeletal muscle and are characterized by the expression of muscle specific basic-helix-
loop-helix (bHLH) transcription factors MyoD and Myf5. In normal adult muscle, satellite cells 
are mitotically quiescent but activated by muscle damage to expand their progeny of 
myogenic precursor cells prior to formation of muscle fibers. Importantly, a continuous supply 
of satellite cells for the damaged muscle fibers is essential for successful long term therapy. 
Recently, Dr. Asakura lab cloned new type of bHLH transcription factors from satellite cell 
cDNA, termed Mouse Achaete Scute Complex Homolog 3, 4 and 5 (MASH3, MASH4 and 
MASH5). MASH4 is expressed in quiescent satellite cells while MASH3 and MASH5 are 
expressed in differentiating satellite cells. The functions for these three genes on satellite cells 
remain to be found. Since bHLH genes play essential roles in many different cell-type 
determination and differentiation, MASH3, MASH4 and MASH5 genes must possess 
important functions on satellite cells. The luciferase reporter gene assay demonstrates that 
MASH3, MASH4 and MASH5 cannot execute E-box mediated transcriptional activation but 
rather suppress other bHLH transactivation. This result suggests MASH3, MASH4 and 
MASH5 may play an important role in suppression of myogenic differentiation and in 
maintenance of quiescent status of satellite cells through suppression of MyoD and Myf5. 
Furthermore, over-expression for MASH3, MASH4 or MASH5 may convert myoblasts to more 































Contracture in the Mdx Mouse Model of Duchenne Muscular Dystrophy 
 
Kristen A. Baltgalvis1, Michael Garlich2, Jarrod A. Call2, Lisa Dorsey2, and Dawn Lowe2 
1 Department of Biochemistry, Molecular Biology, and Biophysics, and 2 Department of 
Physical Medicine and Rehabilitation, University of Minnesota 
 
Muscle contractures are one of the most debilitating aspects of Duchenne Muscular 
Dystrophy (DMD) for children, because it makes walking increasingly difficult as the disease 
progresses.  A gradual decrease in ankle range of motion (ROM) concurrent with false 
hypertrophy of the gastrocnemius muscle typifies the progression of contractures in boys with 
DMD as they lose the ability to walk efficiently. A mouse model of DMD, the mdx mouse, has 
been used extensively in disease research, but the presence of contractures has not been 
investigated.  The primary purpose of this study was to develop measurements in order to 
determine the presence or absence of contractures in the hindlimb of the mdx mouse.  Range 
of motion, in vivo passive torque (Figure 1), and in vivo active torque about the ankle were 
measured on 8 wildtype (wt) and 6 mdx mice over the course of 12 wk.  Mdx mice had ~10o 
less dorsiflexion compared to wildtype mice.  Passive torque was also about 50% greater in 
mdx mice compared to wild-type mice as the ankle was pushed into 20° of dorsiflexion 
(Figure 2).  The passive-to-active torque ratio was also higher in mdx mice relative to wt mice.  
Together, these results indicate that mdx mice have plantarflexion contractures similar to 
those seen in children with DMD.  Future studies can be designed to investigate treatments 
preventing the development of contractures in the mdx mouse and to delineate the 
relationship between contractures and muscle weakness. 
 
Figure 1.  Examples of passive range of motion about the ankle in the mdx mouse.   




Figure 2.  Passive torque of the mdx mouse increases as the ankle is moved into dorsiflexion.   




Altered Response to Mechanical Stress in Isolated Hearts of Mdx Mice 
 
Matthew Barnabei1, 2, Joseph Metzger2  
 
1Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, 
2Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis 
 
Duchenne muscular dystrophy is a lethal inherited disease affecting 1 in 3500 males.  
Although historically thought of as a skeletal muscle disease, 20% of Duchenne deaths are 
due to heart failure.  Previously, our lab has shown that isolated mdx myocytes show 
enhanced susceptibility to stretch-induced injury.  Specifically, mdx myocytes are abnormally 
stiff and show increased membrane permeability, unregulated calcium influx and contracture 
following stretch within a normal physiological range.  To study the effects of dystrophin in the 
response to mechanical stress in an intact, beating heart, isolated mouse hearts were 
subjected to mechanical stress by incrementally increasing the volume, and subsequently, the 
pressure, within the left ventricle.  Surprisingly, as left ventricular volume was increased, the 
resultant increase in left ventricular end diastolic pressure was blunted in mdx mice compared 
to wild-type controls.  This difference was not affected by perfusate calcium concentration and 
mdx mice showed no difference in systolic function through the volume challenge compared 
to wild-type mice.  These findings support dystrophin’s role in stabilizing the sarcolemma in 
response to the mechanical stress associated with contraction and relaxation and shed light 
on how dystrophin deficiency affects the mechanical function of the heart.  
 
 
MiR208 Prevents Phenylephrine Induced Hypertrophy in Adult Rat Cardiac 
Myocytes 
 
Fikru B Bedada, Erik Arden, Joseph M. Metzger 
 
Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN 55455, 
USA 
 
MicroRNAs (miRNAs) are short endogenous RNAs that act as post-transcriptional regulators 
of gene expression by base-pairing with their target mRNAs. Recent study has described 
miR-208 as cardiac-specific regulator of ßMHC expression in response to stress. Deletion of 
the miR-208 in mice caused inhibition of ßMHC expression and protection against 
hypertrophy in response to TAB and calcineurin over-expression. Our study examines the 
effect of exogenously administered miR208 in normal and alpha adrenergic agonist 
stimulated adult rat ventricular cardiac myocytes. We show that Phenylephrine (PE) caused a 
significant change in myocyte structure, namely sending out lamelipodia, increase in size with 
mean ± SEM (2638 ± 96.66, 2561 ± 169.3, 3391 ± 132.5 and 2440 ± 103.3, p<0.05) 
respectively for, miR-208, miR-208+PE, PE and wild type myocytes. Typically, there were 
areas of deposition of new myofilaments detected by alpha actinin staining in the lamelipodia 
of the myocyte which is also co-localized with the Non-Muscle Myosin IIB (NMMIIB). 
Interestingly, miR208 fully blocked this cellular remodeling and abrogated the hypertrophic 
effect observed with PE.  Consistent with this, miR-208 negatively regulated expression of 
GATA4 and calcineurin which are key players of cardiac hyperthrophy. Further, miR-208 
prevented cardiac remodeling induced by GATA4 and calcineurinAß expressing viruses. 
Functionally, PE treated cardiac myocytes showed poor mechanical contraction and 
relaxation which is corrected by miR-208. Together, miR-208 prevents myocardial 
hypertrophy when expressed in rat ventricular cardiac myocyte prior to the application of PE. 
These observations suggest that miR208 is involved in a complex pathway regulating 
hypertrophy. Thus miR208 may hold promise for the design of therapies that prevent 
hypertrophy and consequent heart failure. [This work was supported by NIH] 
Development of a muscleblind-like 1 (Mbnl1) overexpression model to 
assess the use of MBNL1 as a potential therapeutic for myotonic 
dystrophy 
 
Christopher M. Chamberlain and Laura P.W. Ranum 
 
Department of Genetics, Cell Biology and Development and Institute of Human Genetics, 
University of Minnesota, Minneapolis, MN, USA 
 
Myotonic Dystrophy (DM) is the most common form of adult muscular dystrophy.  The 
multisystemic clinical features of DM include myotonia, iridescent cataracts, muscle 
weakness, cardiac arrhythmia, testicular failure, insulin insensitivity, and cognitive impairment.  
This autosomal dominant disorder  is caused by either a CTG trinucleotide repeat expansion 
in the 3’ UTR of dystrophia myotonica protein kinase (DMPK) in DM type 1 (DM1) or a CCTG 
tetranucleotide repeat expansion in the first intron of zinc-finger 9 (ZNF9) in DM type 2 (DM2).  
Several lines of evidence support a novel RNA gain of function mechanism in which CUG or 
CCUG transcripts aggregate in the nuclei and bind with RNA binding proteins:   1) DM1 and 
DM2 share clinical features, yet the genes involved are functionally distinct, 2) expression of 
DMPK and ZNF9 proteins is not affected by the expansion, 3) CUG and CCUG transcripts 
aggregate as nuclear foci and co-localize with RNA binding proteins such as muscleblind-like 
1 (MBNL1), 4) mice expressing long CUG repeats share features of DM, and 5) mice lacking 
MBNL1 share features of DM1.  MBNL1 is involved in developmental regulation of alternative 
splicing.  DM patients and mouse models show significant alternative splicing of MBNL1 
targets.  These results are explained by a model where MBNL1 is sequestered by CUG or 
CCUG RNA foci and is not capable of binding its endogenous splice targets.  Adeno-
associated viral delivery of MBNL1 to DM mouse tibialis anterior muscle results in decreased 
myotonia, improved splicing, and diffusion of MBNL1 throughout the nuclei.  To validate 
MBNL1 as a potential therapy for DM, we must show that MBNL1 overexpression has little/no 
toxic effects.  The hypotheses of this project are: 1) Long-term systemic overexpression 
of MBNL in mice will not have toxic effects, and 2) long-term, systemic MBNL 
overexpression in a DM mouse model will alleviate the DM-like phenotype.   We have 
engineered transgenic mice with MBNL1 under the regulation of a chicken beta-actin 
promoter with a CMV (cytomegalovirus) enhancer.  Transgenic lines displaying MBNL1 
upregulation will be tested for viability, muscle histology, RNA splicing, as well as potential 
CNS defects.  These mice will be bred with a DM mouse model to generate doubly transgenic 
DM/MBNL-OE mice.  Doubly transgenic mice will be tested for histological improvements, 
splicing changes, RNA foci, and muscle force production to determine the extent of DM 
phenotype rescue.  These experiments will test the central hypotheses of the project.  An 
essential component of establishing a potential therapy for DM or any disorder is to analyze 
the potential toxicity of the therapy.  This will be the first test of ubiquitous overexpression of 
MBNL1 as a potential therapy for myotonic dystrophy.  The goal of this project is to 
determine the toxicity of MBNL1 in order to further elucidate its potential as a therapy 
for myotonic dystrophy. 
Role of Cytoplasmic β-actin in the Pathogenesis of Spinal Muscular 
Atrophy 
 
Tom Cheever, Kevin Sonnemann and James Ervasti 
Biochemistry, Molecular Biology and Biophysics Department 
 
 
Spinal muscular atrophy (SMA) is an autosomal recessive disorder that results in the 
loss of lower α-motor neurons and skeletal muscle atrophy. Although the gene responsible for 
this disease has been identified as Survival of Motor Neuron 1 (Smn1), how loss of the 
ubiquitously expressed SMN protein leads to selective motor neuron and muscle pathology is 
unknown. SMN predominantly localizes to cell bodies where it participates in snRNP 
biogenesis. However, recent studies have identified SMN throughout neurites in neurons both 
in vitro and in vivo, raising the possibility that SMN may have additional, neuron specific 
functions. It has been hypothesized that in neurons, SMN also participates in the transport 
and localization of specific mRNAs to the growth cones that cap developing neurites. One 
such mRNA trafficked by SMN was recently identified as cytoplasmic β -actin, whose 
localization and local translation is essential for neurite elongation and growth cone guidance 
in vitro. Interestingly, cultured motor neurons from a mouse model of SMA have decreased β-
actin at growth cones, resulting in defects in axon elongation and growth cone structure, as 
well as delocalized voltage-gated calcium channels. The mislocalization and misregulation of 
β-actin could thus hinder motor neuron development and muscle innervation, leading to motor 
neuron death and disease. To test the hypothesis that β-actin is a downstream mediator of 
SMA pathogenesis, we are generating motor-neuron specific β-actin knock-out mice and 
characterizing motor neuron development and function through physiological and histological 
analysis. These studies will elucidate the role of β-actin in the pathogenesis of SMA. 
 
The Mechanism of Cardiac Failure 
Does it result from a primarily contractile problem or decreasing ATP 
levels? 
 
John Foker, Nicholas Befera, Erik Strungs, James Berry, Richard Bianco 
 
Divisions of Cardiothoracic Surgery and Experimental Surgical Sciences at U of M 
 
Background 
Many abnormalities have been described once heart failure is established, however, the basic 
mechanism producing its onset and progression is unknown.  The rat myocardial infarction 
(MI) model allows failure to be studied in normal muscle.  Following the MI, the remaining 
(remote) myocardium (RM) must take over the entire load and maintain an adequate cardiac 
output.  Unfortunately, the RM (in rats and humans) often goes on to fail, with apoptosis and 
remodeling.  The two most general causes would be a primary failure of the contractile 
apparatus, or the energy supply is not able to keep up with demand and [ATP] slowly falls.  
Because the resulting AMP is catabolized, ATP levels have little chance to recover.  We 
tested which mechanism was operative by giving ribose, which is not used as a fuel, and 
whose only action is to greatly stimulate nucleotide synthesis, especially AMP (ATP).  If 
decreased [ATP] were the primary problem, ribose should slow the development of failure. 
Methods 
Lewis rats (N=7 for each group) had central venous infusion pumps placed and 1 day later, 
the left anterior descending artery was ligated just distal to the circumflex artery, resulting in 
infarction of 35% of the LV. Ribose was infused for 2 weeks at 100mg/k/d. Echo analysis was 
carried out at 0, 2, and 4 weeks (2 weeks beyond the infusion). 
Results 
  Weeks 
    0 2 4 
Ejection Fraction (%) Ribose 60+14 56+13* 46+8.0* 
  Control 65+14 29+3 26+4.6 
LV-SD (cm) Ribose 0.39+0.06 0.47+0.22* 0.64+0.09* 
  Control 0.40+0.03 0.73+0.10 0.95+0.07 
RM-WT (cm) Ribose 0.13+0.02 0.18+0.12 0.13+0.03* 
  Control 0.13+0.03 0.10+0.01 0.10+0.01 
LV-DV (mL) Ribose 0.22+0.03 0.38+0.08* 0.57+0.24 
  Control 0.22+0.06 0.61+0.11 0.71+0.25 
LV-SD=systolic diam, LV-DV=diastolic vol, WT=wall thickness; *p<0.05 vs. control 
 
In this model, MI produced LV dysfunction and dilation with thinning of the RM. Ribose 
reduced RM and LV dysfunction following MI as shown. 
Conclusions 
1) Ribose significantly reduced the RM dysfunction (higher EF, less dilation, and reduced
 RM wall thinning) following a MI. 
2) Ribose was continued for only 2 weeks and some functional deterioration occurred by 
 4 weeks suggesting the energy supply/demand imbalance remained. 
3) These data suggest that the mechanism of failure is a decrease in ATP levels, not a 
 primary breakdown of the contractile apparatus. 
Structural characterization of FKBP interactions with RyR channels using 
site-directed fluorescent labeling and FRET 
Razvan L. Cornea, Florentin Nitu, David D. Thomas, and Bradley R. Fruen* 
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota 
 
The 12 kDa FK506-binding proteins (FKBP12 and FKBP12.6) are regulatory subunits of 
ryanodine receptor (RyR) Ca2+ release channels.  To investigate the structural basis of FKBP 
interactions with the RyR1 and RyR2 channel isoforms, we used site-directed fluorescent 
labeling, direct binding measurements, and fluorescence resonance energy transfer (FRET).  
Single cysteines were introduced at five positions distributed over the surface of FKBP12.6.  
Fluorophore attachment at four positions (14, 32, 49, and 85) did not affect high-affinity 
binding of FKBP12.6 to the RyR1, suggesting that these positions are removed from the 
major RyR1 binding interface.  By comparison, fluorophore attachment at one position (41) 
resulted in decreased FKBP12.6 binding affinity.  The orientation of FKBP12.6 bound to the 
RyR1 and RyR2 was examined by measuring FRET from the different positions on FKBP12.6 
to an acceptor attached within the RyR CaM subunit.  FRET was dependent on the position of 
fluorophore attachment on FKBP12.6, and the rank order of FRET efficiency from the different 
positions was the same whether FKBPs were bound to the RyR1 or RyR2 isoform (position 
49 > 85 ≥ 14 > 32).  These results demonstrate that in binding either the RyR1 or RyR2 
channel, FKBP12.6 is oriented such that position 49 is nearest to the RyR CaM subunit.  
These results are consistent with a recent structural model of FKBP12 binding based on 
RyR1 cryo-EM, and point to FKBP loop 39-46 as a key component of the RyR binding 
interface.  Newly-characterized fluorescent FKBPs offer a powerful approach for targeting 
spectroscopic probes to RyR channels. 
 
FRET-based mapping of calmodulin binding to the RyR1 channel 
 
Razvan L. Cornea, Florentin R. Nitu, Katherine Kohler, David D. Thomas, and Bradley R. 
Fruen* 
Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota 
 
Calmodulin (CaM) functions as a regulatory subunit of ryanodine receptor (RyR) channels, 
modulating channel activity in response to changing [Ca2+].  To investigate the structural basis 
of CaM regulation of the RyR1 isoform, we used site-directed labeling of channel regulatory 
subunits and fluorescence resonance energy transfer (FRET).  Donor fluorophore was 
targeted to the RyR1 cytoplasmic assembly by preincubating sarcoplasmic reticulum 
membranes with a fluorescent FK506-binding protein (FKBP), and FRET was determined 
following incubations in the presence of fluorescent CaMs in which acceptor fluorophore was 
attached within the N-lobe, central linker, or C-lobe.  Results demonstrated strong FRET to 
acceptors attached within CaM’s N-lobe, whereas substantially weaker FRET was observed 
when acceptor was attached within CaM’s central linker or C-lobe.  Surprisingly, Ca2+ evoked 
little change in FRET to any of the three CaM domains.  Donor-acceptor distances derived 
from our FRET measurements provide insights into CaM’s location and orientation within the 
RyR1 3D architecture and the conformational switching that underlies CaM regulation of the 
channel.  These results establish a powerful new approach to resolving the structure and 
function of RyR channels. 
Molecular Mechanisms of SCA8 
 
Brian Gibbens, Mindy Moseley, Tao Zu 
 
GCD Department, MCDB&G program, MD center 
 
Myotonic Dystrophy type 1 (DM1) is a multisystemic disease caused by a CTG•CAG 
expansion in the 3’ untranslated region (UTR) of the DMPK (myotonic dystrophy protein 
kinase) gene.  Patients with DM1 have a multitude of clinical features including myotonia, 
myopathy, iridescent cataracts, cardiac arrhythmias, and a specific set of serological 
changes.  Interestingly, the DM1 CTG•CAG repeat expansion mutation has recently been 
shown to be transcribed in both the CTG and CAG directions.  Attempts to determine the 
mechanism of DM1 have generated strong support for an RNA-toxicity model in which CUG 
expansion transcripts cause misregulation of splicing factors such as muscleblind (MBNL1) 
and CUG binding protein 1 (CUGBP1). Dysregulation of these splicing-factors, and in 
particular the loss of MBNL1, results in the aberrant splicing of several pre-mRNAs including 
the skeletal muscle chloride channel (CLCN1) and insulin receptor (IR). These splicing 
abnormalities are believed to underlie many of the multisystemic disease features. 
While studying another CTG•CAG repeat disorder, Spinocerebellar Ataxia Type 8 
(SCA8), our lab has shown that the SCA8 gene locus is expressed bi-directionally resulting in 
the production of two different repeat containing transcripts, ATXN8OS and ATXN8 (Nature 
Genetics 38:758-769). The ATXN8OS transcript contains a large CUG repeat tract.  Research 
on DM1 has demonstrated that long CUG repeat transcripts can cause disease via an RNA 
gain-of-function mechanism involving the sequestration of splicing factors.  The ATXN8 
transcript contains an ORF encoding a nearly pure CAG repeat tract.  Our lab has shown that 
this CAG repeat tract is translated into a polyglutamine (polyQ) protein in SCA8 BAC mice 
and human patients.  Proteins containing abnormally long polyglutamine tracts are 
responsible for a number of diseases including spinobulbar muscular atrophy, dentatorubral-
pallidoluysian atrophy, SCA1, 2, 3, 6, 7, 17, and Huntington’s disease.  Polyglutamine 
proteins are believed to cause disease through protein gain-of-function mechanisms which 
involve the sequestration of cellular factors, the inhibition of cellular processes, and caspase 
mediated apoptosis. 
The SCA8 locus therefore makes two potentially pathogenic transcripts.  Either or both 
of these transcripts could be responsible for the disease but the relative contribution of each 
of these transcripts to disease phenotypes is currently unknown.  The goal of this project is to 
elucidate the effects of each transcript to determine their relevance to disease pathogenesis.  
Transcripts will be knocked down using a shRNA strategy (Chung, 2006).  Current attempts to 
specifically knock down the ATXN8 (CAG) transcript in 293 cells have resulted in 70% 
reduction in polyQ protein.  Future studies will focus on refining the shRNA constructs in 293 
cells, and testing them in primary neuronal cell lines.  Successful constructs will be used to 
generate shRNA mice which can subsequently be crossed to SCA8 mouse models.  Crosses 
will be used to determine if ATXN8 knock down can rescue the histological and behavioral 
abnormalities of the SCA8 BAC mice.  The relative abundance and distribution of polyQ foci 
in the cerebellums of these mice will be scored by immunohistochemistry and coordination 
defects will be tested with rotarod analysis. 
Hormone Therapy And Skeletal Muscle: A Meta-Analysis 
 
Sarah M. Greising, MS1, Kristen A. Baltgalvis, PhD2, Gordon L. Warren PhD FACSM 3, and 
Dawn A. Lowe, PhD FACSM 1 
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There is not a consensus whether or not estrogen affects muscle strength. Therefore, 
our objective was to perform a systematic review and meta-analysis of the research literature 
that compared muscle strength in post-menopausal women who were and were not on 
estrogen-based hormone therapy (HT). To meet this objective, 24 relevant studies were 
found. Effect sizes (ES) were calculated as the standardized mean difference and the meta-
analyses were completed using a random effects model. HT was found to result in a small, 
beneficial effect on muscle strength in post-menopausal women (ES=0.23; P=0.002) that 
equated to a ~5% greater strength for women on HT. A large variation among the 24 studies 
was seen, with effect sizes ranging from -0.56 to 1.15. To address this variability, possible 
moderator variables were explored. Among the 24 studies, various muscle groups were 
assessed for strength and those that benefitted the most were the thumb adductors 
(ES=1.14; P<0.001). This equated to a 17% greater adductor pollicis muscle strength for 
women taking HT compared with those not. Nine studies that compared muscle strength in 
rodents that were and were not estradiol deficient were also analyzed. The ES for absolute 
strength was moderate but not statistically significant (ES=0.52; P=0.08), while estradiol had 
a large effect on strength normalized to muscle size (ES=0.76; P=0.02). Overall, HT was 
found to beneficially affect strength. This result justifies the need to consider skeletal muscle 
as a target tissue in response to HT. In addition, there is a need to further investigate the role 




Allosteric Changes in Phospholamban Structure and Dynamics Regulate 
Sarcoplasmic Reticulum Calcium-ATPase Function 
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The main mechanism of relaxation in cardiac muscle is pumping of Ca2+ ions from the cytosol 
into the sarcoplasmic reticulum (SR). This pumping is performed by Sarcoplasmic Reticulum 
Ca2+-ATPase (SERCA). Phospholamban (PLN) inhibits SERCA and is thereby a crucial 
regulator of cardiac muscle function. A previous study showed how changing the dynamics of 
PLN by mutations can tune the function of SERCA. In this study structural and dynamic NMR 
data is used to explain the difference in SERCA affinity and inhibition between different 
mutants of PLN. We show how these differences between mutants can be explained from 
different rigidity of the membrane-spanning helix. 
Controlling the Inhibition of the Sarcoplasmic Ca2+-ATPase by Tuning 
Phospholamban Structural Dynamics 
Kim N. Ha, Nathaniel J. Traaseth, Raffaello Verardi, Jamillah Zamoon, Alessandro Cembran, 
Christine B. Karim, David D. Thomas, Gianluigi Veglia 
Department of Chemistry 
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Cardiac contraction and relaxation are regulated by conformational transitions of protein 
complexes that are responsible for calcium trafficking through cell membranes. Central to the 
muscle relaxation phase is a dynamic membrane protein complex formed by Ca(2+)-ATPase 
(SERCA) and phospholamban (PLN), which in humans is responsible for approximately 70% 
of the calcium re-uptake in the sarcoplasmic reticulum.  Dysfunction in this regulatory 
mechanism causes severe pathophysiologies.  Here, we used a combination of nuclear 
magnetic resonance, electron paramagnetic resonance, and coupled enzyme assays to 
investigate how single mtuations at position 21 of PLN affects its structural dynamics and in 
turn, its interaction with SERCA.  We found that it is possible to control the activity of SERCA 
by tuning PLN structural dynamics.  Both increased rigidity and mobility of the PLN backbone 
cause a reduction of SERCA inhibition, affecting calcium transport.  Although the more rigid, 
loss-of-function (LOF) mutants have lower binding affinities for SERCA, the more dynamic 
LOF mutants have binding affinities similar to that of PLN.  Here, we demonstrate that it is 
possible to harness this knowledge to design new LOF mutants with activity similar to S16E 
(a mutant already used in gene therapy) for possible application in recombinant gene therapy.  
As proof of concept, we show a new mutant of PLN, P21G, with improved LOF characteristics 
in vitro. 
 
 Structural Dynamics of SERCA and Phospholamban by Fluorescence 
Microscopy 
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 We have investigated the structure of phospholamban (PLB) and its regulation of the 
sarcoplasmic reticulum Ca-ATPase (SERCA) using fluorescence resonance energy transfer 
(FRET) on fluorescent fusion proteins expressed in living cells, and using total internal 
reflection fluorescence (TIRF) on the labeled cytoplasmic domain of PLB.  Fusion proteins 
were created with either the donor fluorophore, cyan fluorescent protein (CFP), or the 
acceptor fluorophore, yellow fluorescent protein (YFP), attached to one terminus of the 
protein of interest.  Both N-terminal and C-terminal fusions of CFP and YFP were made to 
SERCA and N-terminal fusions were made to PLB.  These proteins were expressed and co-
expressed in either SF21 insect cells or HEK-293 cells.  In fluorescence transfer recovery 
(FTR) experiments, FRET was calculated from the recovery of CFP fluorescence due to 
photobleaching of YFP.  The dependence of donor fluorescence on acceptor photobleaching 
showed that PLB exists primarily as oligomers in cells but binds to SERCA exclusively as a 
monomer.  Polarized TIRF of PLB¸ labeled in the cytoplasmic domain helix with bifunctional 
rhodamine (BFR), shows that this domain lies parallel to the membrane surface.  The 
structural and functional effects of PLB phosphorylation and mutation are under investigation.  
This work was supported by NIH (GM27906) and the Minnesota Supercomputing Institute. 
Structure Function Analysis of Disease-Causing Missense Mutations in 
Dystrophin 
 
Davin M. Henderson, Ann Lee, and James M. Ervasti 
 
 Duchenne muscular dystrophy (DMD) affects 1 of every 3500 males and results in 
death during the mid to late twenties.  Mutations in the dystrophin gene leading to DMD 
commonly result in loss of protein expression or expression of a truncated protein lacking 
essential ligand binding domains.  In some cases, point mutations leading to a single amino 
acid change in the dystrophin protein cause DMD, Becker muscular dystrophy or X-linked 
cardiomyopathy.  Of the known disease causing mutations, 9 are located in the N-terminal 
actin-binding domain of dystrophin.  Examining the effects of these mutations on actin binding 
activity will lead to a better understanding of key residues for dystrophin function in vivo. With 
this in mind, we engineered all 9 N-terminal disease-causing mutations into the full-length 
dystrophin cDNA and have begun to characterize the biochemical properties of each mutant 
protein expressed in the baculovirus system. We have found that the R82P and A172P 
mutants did not express well enough to enable further biochemical characterization.  We have 
analyzed four mutants K18N, L54R, D165V and L172H for their ability to bind F-actin and 
found that K18N and L54R decrease the affinity for F-actin by 3-4 fold.  The L172H mutation 
affects the solubility but not the actin binding properties of the full-length dystrophin protein.  
In fact, all mutations generated in the tandem calponin homology domain of dystrophin were 
consistently less soluble and more aggregated than WT dystrophin. These data suggest that 
the disease phenotypes associated with miss-sense dystrophin mutations are caused by 
either loss of solubility or a combination of insolubility and decreased F-actin affinity.  We also 
found that mutations that cause a more severe disease phenotype (K18N and L54R) bound 
actin with a lower affinity and were less soluble than WT dystrophin.  
  
Transgenic over-expression of gamma-cytoplasmic actin protects against 
eccentric contraction-induced injury in mdx mice 
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Alpha-skeletal actin is the predominant actin species present in adult skeletal muscle, with 
small amounts of cytoplasmic actins also expressed.  Unfortunately, the role of cytoplasmic 
actins in skeletal muscle is not well understood.  We previously reported that levels of 
gamma-cytoplasmic actin are elevated in dystrophin-deficient mdx mouse skeletal muscle 
(Hanft, PNAS, 2006; Prins, PLoS ONE, 2008).  To investigate how elevated levels of 
gamma-cytoplasmic actin may affect the dystrophic phenotype, we transgenically over-
expresssed gamma-cytoplasmic actin specifically in mdx skeletal muscle (mdx-TG mice).   
Levels of gamma-cytoplasmic actin in mdx-TG skeletal muscle were elevated 200-fold 
compared to mdx skeletal muscle and showed incorporation into thin-filaments.  Gross over-
expression of gamma-cytoplasmic actin did not improve or exacerbate mdx muscle pathology.  
However, mdx-TG skeletal muscle had significantly increased twitch force and specific tetanic 
force during eccentric contractions. Moreover, gamma-cytoplasmic actin over-expression was 
able to protect against force loss after initial eccentric contractions.  Further investigation into 
gamma-cytoplasmic actin’s ability to protect mdx muscle during lengthening contractions may 
lead to insight into the mechanism of eccentric contraction-induced injury in dystrophin-
deficient muscle.  
 
Molecular pathophysiology and CNS effects in mouse models of myotonic 
dystrophy types 1 & 2 
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Myotonic dystrophy (DM) is a multisystemic disease that significantly affects the CNS causing 
abnormal cognition, behavioral abnormalities and progressive memory problems. DM is 
caused by non-coding CTG or CCTG expansions in the DMPK (DM1) or ZNF9 (DM2) genes, 
respectively. Although in skeletal and cardiac muscle, an RNA gain-of-function mechanism 
involving the accumulation of CUG/CCUG expansion transcripts, the sequestration of the 
RNA binding protein muscleblind (MBNL1), and downstream alternative splicing changes is 
well established, almost nothing is known about pathophysiology and molecular CNS effects. 
To investigate CNS RNA gain-of-function effects in DM1 and DM2, functional cerebellar 
optical imaging studies were performed on newly developed DM1 and DM2 mouse models 
and a MbnlΔE3/ΔE3 loss-of-function model of DM. 
 We developed multisystemic transgenic mouse models of DM1 and DM2. TRE-
(CCTG)300 expansion mice were crossed to BAC mice expressing the tet-inducible 
transactivator (tTA) under the control of either the endogenous human DMPK or ZNF9 
promoter. Doubly transgenic DM1-CCUG [TRE-CCTG(300):DMPK-tTA] and DM2-CCUG 
[TRE-CCTG(300):ZNF9-tTA] mice show broad expression and multisystemic phenotypes in 
skeletal muscle and brain.Flavoprotein optical imaging studies of DM2-CCUG and 
MbnlΔE3/ΔE3 mice in vivo show a marked reduction in mGluR1 dependent parallel fiber-
Purkinje cell long-term potentiation (PF-PC LTP). 
The effects of estrogen depletion on skeletal muscle metabolism 
 
Allison M. Kosir and Dawn A. Lowe 
Department of Physical Medicine and Rehabilitation 
 
Skeletal muscle plays a significant role in altering metabolic activity of the body by 
influencing blood lipid profiles and insulin sensitivity through enzymatic processes. Hormones 
such as estrogen have been shown to affect skeletal muscle function. Thus, the metabolic 
influence of skeletal muscle function may be altered by the depletion of estrogen. Through its 
role in energy metabolism and expenditure, skeletal muscle likely influences the development 
of cardiovascular risk factors, including, diabetes, dyslipidemia, and obesity.  
To study the effects of estrogen depletion on skeletal muscle metabolic activity, 17 
female C57BL/6 mice were randomly divided into two groups for the duration of 60 days, 
ovariectomized (OVX) and non-OVX. Circulating concentrations of total cholesterol, high–
density lipoprotein (HDL), and glucose were measured prior to ovariectomy surgery and at 20, 
40, and 60 days post-surgery. Pre and post trial measurements of body composition were 
measured on an EchoMRI. Body weight was measured weekly and food intake was 
calculated during a one week period. Twenty-four hour cage activity was monitored in activity 
chambers at 50 days post-surgery. Grip strength and whole body tension evaluation of 
voluntary muscle performance was also assessed.  Additionally, in vivo measurements of 
maximal muscle strength were made.  After 60 days, mice were euthanized and muscle 
tissues, para-ovarian fat pads, and uteri were removed and weighed. To evaluate lipid 
oxidation and glycolytic enzymatic activity, two assays were performed on the soleus muscles 
and tibialis anterior (TA) muscles: β-hydroxy acyl-CoA dehydrogenase (β-HAD) and citrate 
synthase (CS), respectively. Protein content was measured using the bicinchoninic acid 
protein assay.  
After 60 days, OVX mice tended to have higher total cholesterol, lower HDL-to-total 
cholesterol ratios, and higher glucose serum levels. The EchoMRI measurements revealed no 
difference in body fat between surgical groups, however a change in lean mass and total 
body water mass in both OVX and non-OVX mice was observed over time. Body mass 
increased more in the estrogen-deficient mice over time but there was no difference in food 
intake between OVX and non-OVX mice. OVX mice tended to exhibit less cage activity. Grip 
test measurements were not different between surgical groups but OVX tended to have less 
whole body tension. In vivo muscle strength measurements revealed no significant 
differences.  When comparing tissue masses, OVX had lower uterine masses per gram of 
body weight and higher fat pad masses compared to non-OVX.  Total protein content and 
enzymatic activities were not different between muscles from OVX and non-OVX mice.  
Collectively, we found that 8 wk of ovarian hormone depletion had minor effects on 
cholesterol and glucose blood levels, body mass and composition, physical activity and 
muscle strength, uterine and fat pad masses, and muscle protein content and enzymatic 
activity. These subtle changes occurred over a relatively short period of time following 
ovariectomy, and perhaps long-term effects of estrogen-depletion had not yet been 
established and subsequently translated to whole-body effects. If this holds true, then longer-
term studies will be warranted to determine whether the cellular adaptations eventually 
translate to whole-body effects such as the development of increased total cholesterol with 
lower levels of HDL, obesity, and diabetes, which are known risk factors for cardiovascular 
disease. 
Stoichiometry of Dystrophin, Dystroglycan and Laminin in Skeletal Muscle 
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Muscular dystrophy is a category of hereditary diseases that are characterized by progressive 
muscle weakness, muscle degeneration, muscle fibrosis and other associate symptoms such 
as cardiopulmonary complications and nervous system malfunction. Studies on the genetic 
and molecular causes of muscular dystrophies reveal that deficiency in dystrophin-
glycoprotein complex (DGC) is the key of most types of muscular dystrophy. The DGC 
consists of two core proteins – a cytoplasmic protein dystrophin (DYS) and a transmembrane 
protein dystroglycan (DG). On the cytoplasmic side of sarcolemma, DYS binds to F-actin and 
DG. On the extracellular side, DG binds to laminin (LAM), an extracellular matrix protein. 
Together, these proteins form an axis of F-actin-DYS-DG-LAM from cytoplasm across 
sarcolemma to extracellular space, linking cytoskeleton to extracellular matrix, which has 
been proven to play an important structural role in stabilizing sarcolemma and transmitting 
force across sarcolemma during muscle fiber contraction. Further studies reveal that DG also 
plays an important role in basal membrane assembly, cell signaling and neuromuscular 
junction formation. Interestingly, these functions are less or not affected by disruption of other 
components of the DYS-DG-LAM axis then by disruption of DG, which indicates that there 
might be “free DG” that works without being incorporated into DGC complex. To test this 
hypothesis, we used quantitative western blot to quantify the absolute concentration of DYS, 
DG and LAM in skeletal muscles and found out that the molar stoichiometry of DYS:DG:LAM 
in skeletal muscle was 1:40:1, indicating a large fraction of DG might not be incorporated in 
DGC. We also used dystrophin antibody to coimmunoprecipitate DGC. The result showed 
only a small fraction of DG associated with DYS, further confirm the existence of “free DG”. 
 
Dystrophin and utrophin have distinct effects on the microsecond 
dynamics of actin 
 
Ewa Prochniewicz, Davin Henderson, Ava Yun Lin*, James Ervasti and David D. Thomas 
 
This study addresses the molecular mechanisms of actin’s interaction with dystrophin and 
utrophin, in relationship to the pathology of Duchenne muscular dystrophy (DMD) and X-
linked cardiomyopathy. Dystrophin and utrophin bind actin in vitro with similar affinities, but 
with different molecular contacts. It has been proposed that these differences alter the 
elasticity of actin-dystrophin and actin-utrophin linkages to the sarcolemma, affecting the cell’s 
response to muscle stretches. To test this hypothesis, we have determined the effects of 
dystrophin and utrophin on the microsecond dynamics of erythrosin iodoacetamide-labeled 
actin using transient phosphorescence anisotropy (TPA).  Binding of dystrophin or utrophin to 
actin resulted in significant changes in the TPA decay, revealing similarities as well as 
differences in the structural effects of each protein on actin. At a low level of actin saturation 
(≤20%) both proteins induced similar changes in actin dynamics, but at higher levels of 
saturation, utrophin was more effective than dystrophin and induced more pronounced 
changes in the final anisotropy, correlation time, and initial anisotropy of actin. The simplest 
interpretation of these changes is that utrophin restricted the amplitude and increased the 
rates of motion of the probe to a substantially larger extent than dystrophin. Further analysis 
indicated that the actin-utrophin complex is much more torsionally flexible than the actin-
dystrophin complex. We propose that these differences between dystrophin and utrophin in 
their effects on actin dynamics affect elastic properties of actin-mediated linkages with the 
sarcolemma.  Preliminary data on fragments containing all the proposed actin binding 
domains (DN-R17/UN-R10) show less effect on regulating rotational amplitude and nearly no 
effect on rotational rate. Future experiments looking at other fragments of dystrophin and 
utrophin and their functionally relevant mutants will determine which structural elements of 
these proteins are critical in determining the flexibility of actin filaments and what level of actin 
flexibility is physiologically optimal. This will greatly aid in both the therapeutic designs to treat 
dystrophin deficiency in both the skeletal and cardiac muscles. 
 
Biophysical Engineering of the PLB-SERCA Interaction for Treatment of 
Heart Failure 
 
Elizabeth L. Lockamy, Bonnie M. Fedor, Christine B. Karim, Joshua Palmer, Razvan Cornea, 
and David D. Thomas 
 
Department of Biochemistry, Molecular Biology, and Biophysics 
University Minnesota, Minneapolis 
 
We are using solid-phase peptide synthesis of phospholamban (PLB), functional 
membrane reconstitution of PLB with its regulatory target (SERCA, the cardiac calcium 
pump), and fluorescence resonance energy transfer (FRET), with the goal of designing 
drugs or peptides for heart failure therapy.  It has been proposed that heart failure can be 
treated by decreasing, but not eliminating, the inhibitory effect of PLB on SERCA.  We have 
developed a quantitative in vitro approach, involving a microplate-based FRET assay, to 
detect the physical interactions of PLB and SERCA in reconstituted membranes.  The idea 
is that an unlabeled drug or peptide that displaces labeled PLB from labeled SERCA (and 
thus relieves SERCA inhibition) will decrease FRET.  The present study focuses on the 
synthesis of a series of loss-of-function PLB variants, which we have probed for their ability 
to displace labeled wild-type PLB from SERCA, as detected by a decrease in FRET.  Second, 
we have engineered truncated PLB variants, in order to generate a soluble reagent, which 
would be more useful for therapeutic delivery.  The results are promising on both fronts: (1) 
We have identified two loss-of-function PLB variants that displace ST-PLB from SERCA and 
relieve its inhibition.  (2) We have created a truncated PLB variant that is water-soluble and 












Fig. 1:.  
CCUG RNA gain-of-function effects in a conditional mouse model of 
myotonic dystrophy type 2 (DM2). 
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We developed a tetracycline inducible murine model of DM2 to test the hypotheses 
that CCUG300 expansion transcripts expressed in the absence of the endogenous gene 
context, are sufficient to replicate the skeletal muscle features of myotonic dystrophy and that 
many of these features are reversible. Skeletal muscle from transgenic animals expressing 
transcripts with 300 but not 5 CCUGs show a number of phenotypic changes characteristic of 
myotonic dystrophy including: 1) variation in fiber size and central nuclei; 2) electrical 
myotonia; 3) ribonuclear inclusions; and 4) aberrant splicing of Capzb, Insr, and Clc1. RT-
PCR assays show that the administration of doxycycline to 10 month old animals for 10 
weeks turns off transgene expression and results in the loss of ribonuclear inclusions as well 
as a significant reduction in the number of central nuclei. These studies show that expression 
of (CCUG)300 expansion transcripts as part of an exogenous non-coding transcript is sufficient 
to cause a number of phenotypic characteristics of myotonic dystrophy and that many of the 
pathogenic changes are reversed when expression of the transgene is turned off. 
Additional studies show variable expression of Cugbp1 in (CCUG)300 mice but no 
statistically significant increase in the mutant vs. control groups (p= 0.11). Combined FISH/IF 
studies in skeletal muscle show an increase of Cugbp1 levels in some nuclei, but no 
correlation with the presence or absence of CCUG foci. Unexpectedly, a dramatic increase in 
Cugbp1 protein (p = 0.0085), but not RNA, was found in a chloride channel (ADR) knock-out 
mouse but not in other mouse models of muscle disease (mdx-/- and mdx-/-/utr-/-). Additionally, 
Mbnl1 and CUG-BP2 were also elevated in the ADR but not the (CCUG)300 mice. In 
summary, overexpression of CUGBP1 is not a consistent feature in our (CCUG)300 model and 
upregulation of CUGBP1 is not unique to DM. 
Dominant effect of histidine modified troponin to normalize SR Ca2+ load 
and rescue ischemia/reperfusion deficits in phosholamban deficient 
hearts. 
Joshua J. Martindale, Todd J. Herron, Sharlene M. Day, Nathan J. Palpant, Joseph M. 
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Genetic modification of cardiac Ca2+ handling has been proposed to improve functional 
deficits in the failing heart.  For example, ablation of phospholamban (PLN), a key inhibitor of 
the sarcoplasmic reticulum Ca2+ - ATPase (SERCA2a), causes enhanced cardiac contractility 
and faster relaxation.  However, phospholamban deficient hearts (PLN KO) are highly 
susceptible to increased ischemia/reperfusion (I/R) injury.  We hypothesized that histidine-
modified cardiac troponin I, cTnI (A164H), which has increased Ca2+ sensitivity especially 
during ischemia/acidosis, could rescue PLN KO hearts from I/R mediated functional deficits.  
Isolated PLN KO hearts exposed to I/R exhibited dramatically reduced recovery after 1 hr of 
reperfusion compared to controls (2.5% +/- 1.4% recovery vs 32.5% +/- 9.3%, P<0.05), 
highlighting a major deficiency in PLN KO hearts.  Interestingly, expression of cTnIA164H had 
nearly a 14-fold improvement and restored functionality to PLN KO hearts (34.7% +/- 8.5% 
recovery).  Echocardiography of mice exposed to 10 minutes acidosis (40% CO2) showed 
that cTnIA164H improved ejection fraction, stroke volume, and cardiac output in PLN KO 
mice in vivo.  Immunoblot analysis of the calcium handling proteins SERCA and calsequestrin 
did not show any differences between PLN KO hearts and PLN KO hearts expressing 
cTnIA164H.  As PLN KO hearts have been shown to have increased SR Ca2+ load, we 
sought to determine whether cTnIA164H has an effect on Ca2+ dynamics.   PLN KO myocytes 
have a nearly two-fold increase in caffeine-induced SR Ca2+ release compared to control, 
consistent with previous results.  Surprisingly, PLN KO myocytes expressing the cTnI A164H 
transgene had normalized caffeine-releasable SR Ca2+ load, yet still maintained the rapid SR 
Ca2+ uptake characteristic of PLN KO myocytes.  These findings suggest a new paradigm of 
Ca2+ handling in the heart by indicating a dynamic interplay between SR and myofilaments, 
with cTnIA164H myofilaments having a dominant effect to normalize SR Ca2+ load and rescue 
ischemia/reperfusion deficits in hearts with dysregulated Ca2+ pumps.  
MR spectroscopic and kinetic investigations of the interaction of Protein 
Kinase A with phospholamban and phospholamban mutants 
 
Larry R. Masterson* and Gianluigi Veglia† 
 
Departments of Chemistry* and Biochemistry, Molecular Biology, and Biophysics† 
University of Minnesota, Minneapolis, MN 55455 
 
The Catalytic-subunit of Protein Kinase A (PKAc) mediates the phosphorylation of a number 
of proteins in cardiomyocytes which, in turn, governs myocardial contraction and relaxation.  
Although a wealth of kinetic and atomic-level structural data is available for the interactions of 
PKAc with standard, largely non-physiologically relevant substrates, these data are nearly 
absent for the interactions with substrates found in cardiomyocytes.  Phospholamban (PLN) is 
a substrate of PKAc in cardiomyocytes, where it regulates the sarcoplasmic reticulum Ca2+-
ATPase.  Phosphorylation of PLN allows the relief of its inhibitory affects on Ca2+ transport 
into the sarcoplasmic reticulum.  Here, we investigate the interactions of PKAc with PLN using 
a variety of biophysical techniques which include NMR spectroscopy, isothermal calorimetry 
(ITC), and steady-state kinetic assays.  Kinetic assays were used to define the steady-state 
kinetic parameters for the catalytic efficiency of phosphorylating PLN and two mutants of PLN, 
R9C and R14-delete.  The ability of PKAc to bind these proteins was also measured using 
ITC to investigate any differences in binding affinity.  Finally, TROSY-based NMR 
spectroscopy was used to observe and map the residue specific differences in the amide 
fingerprint of PKA-C when bound to each of these substrates.  These data will be presented 
to model the effects of PLN mutations on the interactions with PKAc. 
Compensatory adaptation of protein expression in 
resistance-trained dystrophic mouse muscle 
 
Jim McKeehen1, Jarrod Call2, Kristen Baltgalvis3, and Dawn Lowe2 
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 The purpose of this pilot study was to determine if muscles of exercise-trained mdx 
mice upregulate structural proteins α 7 β 1 integrin, utrophin, and β-dystroglycan as a 
compensatory adaptation to their absence of dystrophin.  We modeled resistance exercise 
training using resisted training wheels.  At 25 days of age, WT mice were separated into 3 
groups: sedentary (n=4), resistance training (n=5), and no resistance training (n=4).  25 day-
old mdx mice were separated similarly: sedentary (n=5), resistance training (n=2), and no 
resistance (n=1).  The resistance wheel mice were introduced to the wheel with only 1 g of 
resistance for 1 wk, which was then increased to 4 g at Wk 2 and 7 g at Wk 3&4. The no 
resistance wheels had <1 g resistance throughout the study. After a total of 4 weeks all mice 
were sacrificed and triceps muscles were dissected for protein analysis using Western 
Blotting techniques.  Free wheel mice ran more than8. km/day while resistance wheel mice 
ran ~ 50% less, however resistance mice did approximately 3-fold more work than free wheel 
mice.  As a result, preliminary western blot results show that resistance-trained mice had 
~17% more β-dytroglycan protein than sedentary mice.  The upreguation of specific structural 
proteins in mdx mice as a compensatory adaptation to resistance wheel training may be even 
better realized after we complete our current 12 Wk study using 34 mdx mice. 
 
EPR Analysis of Myosin Structural Dynamics in a Pre-power Stroke 
Conformation 
 
Ryan N. Mello1, Leanne J. Anderson1, Andrew Thompson1, Jason W. Sidabras2, James 
S. Hyde2, David D. Thomas1 
 
1University of Minnesota, Minneapolis, MN, USA, 2Medical College of Wisconsin, Milwaukee, 
WI, USA. 
 
Cross-linking the two most reactive Cys of the myosin catalytic domain (CD) (SH1 and SH2) 
inhibits force production and ATP hydrolysis and locks myosin in a weak actin-binding 
conformation.  Recent work using a bifunctional spin label (BSL) to crosslink SH1 and SH2 
has shown that the CD is immobilized and orientationally disordered, suggesting that cross-
linking traps myosin in a an intermediate state that primes the myosin head to generate force 
(Thompson et al., 2008).  Fig. 2 illustrates this intermediate state in the traditional actomyosin 
ATPase cycle.   In the present study, 
we measured light chain domain 
(LCD) structural dynamics in muscle 
fibers as a function of SH 
crosslinking.  If the CD really is 
orientationally disordered by 
crosslinking and the two domains are 
structurally coupled, some of this 
disorder should be propagated to the 
LCD.  To measure LCD structural 
dynamics, we used site-directed spin 
labeling to label chicken gizzard 
regulatory light chain (RLC), and then exchanged this labeled RLC for the native RLC in 
rabbit psoas fibers.  Prior to crosslinking, EPR spectra acquired with the fiber axis parallel and 
perpendicular to the external field were very different, but cross-linking decreases this 
difference, indicating increased disorder.  Saturation transfer EPR on these fibers showed 
that the heads remained immobile and thus attached to actin.  These results support our 
hypothesis that SH1-SH2 crosslinking traps an actomyosin complex, possibly the first force-
generating state in the power stroke, in which the CD is highly disordered and LCD is partially 
disordered, indicating a partially flexible linkage.  A secondary goal of this research is to 
improve the technology for EPR on muscle fibers by developing a novel high-sensitivity EPR 
resonator for analysis of spin-label mobility, orientation, and force on labeled fibers. 
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Fig. 2. Actomyosin ATPase cycle adapted from Thompson 
et al., 2009.  Red = Weak binding. Green = Strong binding.   
Arrow indicates orientational disorder. 
Generation of induced pluripotent stem cells from patient-specific FSHD 
myoblasts 
 
Ramiro Nandez, Darko Bosnakovski, Mathew Struck, Nathan Zaidman and Michael Kyba 
 
Lillehei Heart Institute and Department of Pediatrics, University of Minnesota 
 
Facioscapulohumeral muscular dystrophy (FSHD) is a dominant inherited neuromuscular 
disease. The underlying molecular mechanism of the disease is still unknown but 95% of 
patients carry a subtelomeric deletion on chromosome 4q35.2 thought to affect chromatin and 
gene expression in the region. The recent discovery of methods to reprogram somatic cells to 
the embryonic state allows the creation of patient- and disease-specific cells, which can serve 
as a model for the disease, and the possibility of autologous cell therapy with genenetically 
corrected cells. In this study we have generated 3 induced pluripotent stem (iPS) cell lines 
from myoblasts obtained from FSHD patient biopsies as well as a 4th line derived from 
unaffected myoblasts. To induce reprogramming we delivered the classical transcription 
factor quartet (Oct4, Sox2, Klf4, and Myc) by retroviral transduction and also included SV40 
Large-T-antigen to increase the efficiency of reprogramming. These cell lines appear 
indistinguishable from human embryonic stem (hES) cells and express hES markers. We are 
in the process of characterizing each of the clones for gene expression, teratoma formation 
and in vitro differentiation with the intention of understanding the chromatin changes that 
occur at 4q35.2 in FSHD-affected myogenic progenitors.   
 
 
Bone Deterioration in Duchenne’s Muscular Dystrophy 
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The incidence of bone fracture is 18-44% higher in boys with Duchenne’s Muscular Dystrophy (DMD). 
This incidence becomes further elevated after prednisone treatment, which is thought to strengthen 
skeletal muscle while thwarting the progression of DMD. To date, the cause of bone fracture in boys 
with DMD has received little attention; however, it has been well established that bone’s functional 
and geometric properties are tightly regulated by muscular contractions. The combined effect of 
diminished frequency and magnitude of muscular contractions, hallmark features of DMD, is likely to 
compromise bone’s functional and geometric properties. Additionally, prednisone treatment alone has 
a catabolic effect on bone reducing bone volume and strength. However, little is know about how 
prednisone treatment and diminished physical activity affect both tissues simultaneously, particularly 
in muscular dystrophy. Therefore, the purpose of this study was to investigate the effects of 
prednisolone treatment on bone and muscle functions in mdx mice with typical physical activity and 
mechanical loading of bone compared to mdx mice with restricted physical activity and presumably 
reduced loading. Methods: Male mdx mice were given prednisolone (n=8 with typical activity 
(mdx+Pred) or n=8 restricted cage activity (mdx+Pred+RA)) or placebo (n=8 with typical activity 
(mdx)). After 8 wk of treatment, muscle strength was assessed in vivo by stimulation of the anterior 
crural muscles (peak eccentric and maximal isometric torque) and in vitro stimulation of the EDL 
muscle (maximal isometric force). Tibial bone’s functional capacity was assessed by three point 
bending (ultimate load and stiffness) and micro CT (cortical and trabecular bone volume fraction and 
trabecular density). One-way ANOVA was used to determine group differences in bone and muscle 
functional parameters. Results: Following 8 wks of prednisolone treatment,  muscle strength 
remained unaltered for each of the muscle functional parameters (p>0.0.381). In bone, both ultimate 
load and stiffness were 10-14% lower in the mdx+Pred+RA group compared to the mdx and 
mdx+Pred groups (p<0.02 for all), showing that the combination of prednisolone and restricted activity 
resulted in structurally weakened bone. Furthermore, bone volume fractions of both cortical and 
trabecular bone were 20-61% lower in the mdx+Pred+RA group compared to the other two groups 
(Figure 1, p<0.001 for all). Conclusion: Despite the ability of the lower leg muscles of all mdx mice in 
this study to produce similar magnitudes of muscular contractions and torques, the condition of 
reduced physical activity drastically altered bone’s functional and geometric properties making the 
bone substantially weaker. Thus in DMD, the combination of lowered physical activity in addition to 




Figure 1.  Micro CT images of trabecular bone of the proximal 
tibia in mdx mice.  A-C are superior views of 50 stacked 
images, and D-F are the same 50 slices rotated to better 
represent the cross-section of bone used in the analyses.  A 
and D are mdx, B and E are mdx+Pred, and C and F are 
mdx+Pred+RA.  
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Single Histidine Button in Cardiac Troponin I Sustains Heart Performance 
in Response to Severe Acidosis In Vivo 
 
Nathan J. Palpanta, Louis G. D’Alecya, and Joseph M. Metzgerb. 
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Intracellular acidosis is a profound negative regulator of myocardial performance. The aim of 
this study was to test the effect of a unique bio-sensor in modulating cardiac performance in a 
pH-dependent manner. We hypothesized that titrating myofilament calcium sensitivity by a 
single histidine substituted cardiac troponin I (cTnI A164H) would act as a molecular rheostat 
protecting the whole animal physiological response to acidosis in vivo.  Methods/Results: 
Severe acidosis was induced in mice by ventilation with 40% CO2. Echocardiographic 
analysis showed that systolic function and ventricular geometry were maintained in Tg mice. 
By contrast, nontransgenic (Ntg) littermates experienced marked deterioration in global 
cardiac performance and significant LV dilation during this same challenge. For detailed 
hemodymanic assessment, cardiac conductance micromanometry analysis was performed. 
To specifically isolate intrinsic cardiac performance during acidosis, animals were treated with 
a beta blocker during ventilation with 40% CO2. Hemodynamic analysis during beta blockade 
and acidosis showed that Ntg mice underwent marked cardiac decompensation with 100% 
mortality within five minutes. In contrast, Tg mice maintained systolic and diastolic function 
and had 100% survival during the twenty minute time course of the challenge. At the end of 
the challenge and severe acidemia (pH = 6.5) numerous measures of cardiac performance in 
Tg mice were not significantly different from baseline based on a Dunnets test. Conclusion: 
This study shows that, independent of any beta adrenergic compensation, histidine-modified 
cardiac troponin I is a unique myofilament-based molecular bio-sensor that maintains 
contractile function and markedly improves survival during severe acidosis in vivo.  
 
Dystrophin is a Microtubule-Associated Protein 
Kurt Prins, Jill Humston, Amisha Mehta, Evelyn Ralston, and James Ervasti. 
 
Cytolinkers are giant proteins that stabilize cells by linking actin filaments, intermediate 
filaments, and microtubules to transmembrane complexes.  Dystrophin, the protein absent in 
Duchenne muscular dystrophin, is functionally homologous to cytolinkers as it links actin and 
intermediate filaments to a transmembrane complex.   Although no direct link between 
dystrophin and microtubules has been documented, costamere-associated microtubules are 
disrupted when dystrophin is absent.  Using tissue-based cosedimentation assays on mice 
expressing endogenous dystrophin or truncated transgene products, we found constructs 
encoding spectrin-like repeat 24 through the first third of the WW domain cosedimented with 
microtubules.  Purified Dp260, a truncated isoform of dystrophin, bound microtubules with a 
Kd of 0.66 μm, a stoichiometry of 1 Dp260/1.4 α-β tubulin heterodimer at saturation, and 
stabilized microtubules from cold-induced depolymerization.  Finally, α-and β-tubulin 
expression was increased approximately 2.5 fold in mdx skeletal muscle without altering the 
tubulin: microtubule equilibrium.  Collectively, these data suggest dystrophin directly 
organizes and/or stabilizes costameric microtubules, and classifies dystrophin as a cytolinker 
in skeletal muscle. 
Cardioprotective pretreatment for global ischemia of isolated swine 
hearts: assessed using Visible Heart® methodologies 
 
Christopher D. Rolfes, BA1,2, Michael D. Eggen, MS1,2, Eric S. Richardson, PhD3, Paul A. 
Iaizzo, PhD1,2,4  
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Background: The total number of heart transplanted in the US could be greatly increased by 
increasing viable time outside the body.  Drug delivery into the pericardial space is a method 
that could not only potentially improve function in the transplanted heart, but also prolong 
viability. 
Methods: Docosahexaenoic acid or an equal amount of carrier (a small amount of ethanol) 
was delivered into the swine pericardial space 30 minutes before cardioplegic arrest.  The 
heart was explanted and after cannulation of the great vessels, the heart was reperfused 
using Visible Heart® methodologies for 60 minutes alternating between right sided working 
and full working modes.  Hemodynamic data was taken to assess cardiac function and 
circulating buffer was sampled for protein quantification. 
Initial results: With the current protocol treated hearts take a longer time to fibrillate and 
flatline than controls (p=0.054).  Upon reanimation, the control hearts obtain better pressures 
and elute fewer proteins than the treated hearts, though statistical significance has not been 
achieved.  
Cardiac Myosin Isoform Remodeling in Duchenne Muscular Dystrophy 
Cardiomyopathy 
 
Evelyne M. Houang1 Brent M. Berry, Mihir Pendurkar, and Osha Roopnarine*,2 
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Duchenne muscular dystrophy (DMD) is an inherited neuromuscular disease in humans that 
is caused by a deficiency in the dystrophin protein, which leads to deterioration of skeletal 
muscle and cardiomyopathy.    The finding that cardiomyopathy is not reversed in a gene 
rescue of skeletal muscular dystrophy in a mouse model of the MDC suggests that the 
mechanism for cardiomyopathy is different from skeletal myopathy, so it is important to 
delineate these differences.  The skeletal and cardiac muscle fibers from a mouse model 
lacking the dystrophin gene, (called mdx mouse) show decreased force generation indicating 
that contractile proteins are affected by the absence of dystrophin, suggesting a downstream 
effect of the DMD disease.  Also, this further implies that a force-determining muscle protein 
in the muscle (e.g. myosin) is affected by the absence of dystrophin.  Previous studies show 
that in the skeletal muscle of DMD mice, myosin undergoes an isoform shift from the fast to 
the slow isoform; therefore it is plausible that cardiac myosin undergoes similar transitions.  It 
is unknown if cardiac myosin is remodeled in DMD cardiomyopathy patients or mice, as is 
observed during diabetes, failing hearts, and aging. The first specific aim of the proposed 
research is to determine whether cardiac myosin undergoes isoform remodeling in dystrophic 
mice hearts from two mouse models; one lacking dystrophin (mdx) and another lacking both 
dystrophin and utrophin (mdx/utrn-/-).  Our results show that cardiac α-myosin is remodeled to 
β-myosin to a higher extent in the LV papillary muscle of mdx:utrn-/- mice than in the LV or RV 
muscles.  We also observed β-myosin in the mdx muscle at lower levels compared to the 
mdx:utrn-/- muscle, but not in the WT samples.   The second specific aim of our study is to 
determine whether other sarcomeric muscle proteins undergo alterations in their expression 
levels.  Our proposed research is designed to clarify and give insight into the role of cardiac 
myosin in DMD cardiomyopathy. Supported by funds from a Nash Avery Award to OR and 
Gregory Marzolf Fellowships to EMH  and MP from the Paul and Sheila Wellstone Muscular 
Dystrophy Center at the Univ. of Mn, and by funds from the NIH-NIAMS R01 grant 
(AR052360) to OR.  
 
 
Analysis Of The Sarcolipin:Serca Regulatory Complex Using Fluorescence 
Resonance Energy Transfer Microscopy 
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We have used fluorescence resonance energy transfer (FRET) microscopy  to identify 
physical interactions between the sarcoplasmic reticulum Ca-ATPase (SERCA) and its 
regulatory subunit sarcolipin (SLN) from fast-twitch skeletal muscle. SLN is a 
phospholamban-like protein that inhibits calcium cycling by decreasing the calcium affinity of 
SERCA. It is not known whether SLN forms pentamers like phospholamban, nor is it known if 
SLN monomers or oligomers bind to SERCA. Here we express fluorescent fusion proteins of 
SLN and SERCA to monitor molecular interactions between the two proteins. FRET 
microscopy in live cells has demonstrated that SLN monomers self-associate to form dimers 
and that SLN monomers interact with SERCA monomers to form 1:1 binary complexes. FRET 
results further demonstrate that the binding affinity of SLN:SLN homo-dimers is about equal to 
the binding affinity of SLN:SERCA hetero-dimers. Site directed mutagenesis demonstrated 
that Isoleucine-17 of SLN decreased FRET in half for both SLN:SLN and SLN:SERCA 
interactions. We conclude that (1) SLN monomers compete in equilibrium between SLN 
oligomerization and SERCA binding and (2) Isoleucine-17 of SLN participates in both types of 
interactions. 
 
The Effects of Tissue Bath pH During Hypoxia on an In Vitro  
Ischemia / Reperfusion Injury Model 
 
Vidur Sharma, Charles L. Soule, and Paul A. Iaizzo 
Department of Surgery, University of Minnesota 
 
Muscle recovery from ischemic conditions is inhibited by factors such as increased 
metabolic waste, increased levels of CO2, and low pH environment. Interestingly, many in 
vitro ischemia / reoxygenation models, utilize a buffering system that maintains a normal pH 
of about 7.4 during the ischemia phase(1-2). The goal of this research was to modify the 
incubation conditions of our in vitro hypoxia muscle model to better simulate in vivo ischemia / 
reperfusion injury.  
 Rectus abdominis skeletal muscle bundles from Yorkshire crossbreed swine were 
maintained in a modified Krebs buffer in tissue baths between two platinum electrodes which 
delivered a supramaximal,15 volt, 1 msec stimulus pulse every 10 seconds(1). Peak forces 
were measured as an indicator of the muscle’s viability. The Krebs was continuously gassed 
with either a mixture of 95% O2 and 5% CO2 during normoxia periods or 95% N2 and 5% CO2 
during hypoxia; maintaining a pH of 7.4. In another group the gassing during hypoxia was 
supplemented with CO2 lowering the pH to 6.5. After hypoxia, the bundles were reoxygenated 
for 2 hours. All forces were normalized to their prehypoxia values and reported as percent 
changes over time ± StDev. 
After 2 hours reoxygenation bundles exposed to pH 7.4 hypoxia recovered to 
35.73%±14.92% of their prehypoxia value compared to the pH 6.5 hypoxia force recovery of 
14.73%±6.81%. This indicates that the lower pH during hypoxia reduces the post hypoxia 
recovery of skeletal muscle. Furthermore, when the bundles were preconditioned before 
hypoxia with 10 uM of [D-Pen2,D-Pen5]-Enkephalin (DPDPE), bundles exposed to pH 7.4 
hypoxia recovered to 35.21%±14.02% while the pH 6.5 hypoxia bundles recovery increased 
to 19.16%±12.89%, indicating that DPDPE preconditioning may only benefit the recovery of 
tissue that has been exposed to the more intense hypoxia with a lower pH. 
In another series of experiments, pH 7.4 hypoxia bundles 
were exposed to the free radical H2O2 during reoxygenation. The 
muscle bundles exposed to 1250 uM H2O2 recovered 
32.08%±10.47% of its original peak force while those exposed to 
125 uM H2O2 recovery of 35.79%±8.12% was similar to the pH 7.4 
hypoxia control group at 35.73%±14.92%, suggesting that free 
radicals might play less of a role in the recovery of the muscle from 
hypoxia than the pH during hypoxia. 
In summary, the results of these studies may be applied to 
identifying a better in vitro model of ischemia / reperfusiuon injury of 
striated muscle 
 
1. Hong J, Sigg DC, Coles JA Jr, Oeltgen PR, Harlow HJ, Soule CL, Iaizzo PA: Hibernation 
induction trigger reduces hypoxic damage of swine skeletal muscle. Muscle Nerve. 2005; 
32(2):200-7 
2. Kilian JG, Nakhla S, Sievking DP, Celermajer DS: Adenosine prevents neutrophil adhesion 
to human endothelial cells after hypoxia/reoxygenation. Int J Cardiol. 2005; 105(3):322-6 
TAT-Utrophin crosses cell barriers to combat dystrophin deficiency 
Kevin J. Sonnemann1, Hanke Heun-Johnson1, Amy J. Turner1, Kristen Baltgalvis1, Dawn 
Lowe2, and James M. Ervasti1 
1Dept. of Biochemistry, Molecular Biology, and Biophysics, 2Program in Physical Therapy, 
University of Minnesota, Minneapolis, MN 55455 
The loss of dystrophin compromises muscle cell membrane stability and causes Duchenne 
muscular dystrophy and/or various forms of cardiomyopathy.  Increased expression of the 
dystrophin homolog utrophin by gene delivery or pharmacologic upregulation has been 
demonstrated to restore membrane integrity and improve the phenotype in the dystrophin-
deficient mdx mouse.  However, the lack of a viable therapy in humans predicates the need to 
explore alternative methods to combat dystrophin deficiency.  We investigated whether 
systemic administration of recombinant full-length (Utr) or ΔR4-21 “micro” (μUtr) utrophin 
protein modified with the cell-penetrating TAT protein transduction domain could attenuate the 
phenotype of mdx mice.  Recombinant TAT-Utr and TAT-μUtr proteins were expressed using 
the baculovirus system and purified using FLAG-affinity chromatography.  Age-matched mdx 
mice received six twice-weekly intraperitoneal injections of either recombinant protein or PBS.  
Three days after the final injection, mice were analyzed for several phenotypic parameters of 
dystrophin deficiency.  Injected TAT-μUtr transduced all tissues examined, integrated with 
members of the dystrophin complex, reduced serum levels of creatine kinase, the prevalence 
of muscle degeneration/regeneration, the susceptibility to eccentric contraction-induced force 
drop, and increased specific force production.  These results establish the efficacy and 
feasibility of TAT-utrophin-based constructs as a novel direct protein-replacement therapy for 
the treatment of skeletal and cardiac muscle diseases caused by loss of dystrophin. 
 
Structural dynamics of sarcoplasmic reticulum Ca2+-ATPase (SERCA) 
studied by molecular simulations of site-specific labeled protein 
 
Bengt Svensson1, Deborah L. Winters1, Joseph M. Autry1, L. Michel Espinoza-Fonseca1,2,  
Elizabeth L. Lockamy1 and David D. Thomas1 
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Structural dynamics of the proteins involved in Ca2+ transport and its regulation is studied 
in our laboratory by EPR and fluorescence spectroscopy. To interpret these experimental 
results and to generate new structural and mechanistic models, we have performed 
computational simulations of SERCA labeled with spectroscopic probes. Our approach 
provides information on the conformational landscape sampled by SERCA during its catalytic 
cycle.  
X-ray crystal structures suggest that the nucleotide-binding and actuator domains of 
SERCA move apart by about 3 nm upon Ca2+ binding, undergoing a transition from open to 
closed conformations.  To test this hypothesis, we constructed a fusion protein containing 
CFP linked to the N-terminus (the A-domain) of SERCA. CFP-SERCA was then specifically 
labeled with FITC in the N-domain. FRET was then used to monitor the A to N interdomain 
distance (Winters, Autry, Svensson and Thomas, 2008, Biochemistry 47, 4246–56). To 
interpret the FRET data, simulations of the CFP-SERCA fusion protein were conducted to 
generate a representative ensemble of conformations. FRET parameters were calculated 
using both distance and orientation information. Based on FRET data and simulations, we 
conclude that (a) the cytoplasmic headpiece maintains a compact structure throughout its 
catalytic cycle, rather than the open E1.Ca crystal structure, and/or (b) the Ca-bound E1 state 
is dynamically disordered and samples both open and closed 
conformations, with an average structure that is only slightly 
different from the closed E2 structure. 
We have developed molecular mechanics force-field 
parameters for the fluorescence labels AEDANS in order to 
perform molecular dynamics simulations on SERCA with the 
label attached to Cys674. These conformational sampling 
simulations of the fluorescent probe and its protein environment 
will enable direct comparisons with fluorescence spectroscopy 
experiments. Time-resolved FRET was measured for the donor 
IAEDANS attached to Cys674 and the acceptor TNP-ADP. The 
high time resolution allows for determination of not only the 
mean distance, RDA, but also the distance distribution (disorder). 
The combined approach of time-resolved fluorescence 
spectroscopy and simulations gives us insight into local 
structural dynamics of SERCA.  
This work was supported by NIH (GM27906, AR007612) and 
the Minnesota Supercomputing Institute. 
 
 
SERCA with the AEDANS 
probe at position 674. The 
region in space which the 
probe samples is 
highlighted. 
MR Imaging of Pacing Induced Ventricular Dyssynchrony in an Isolated 
Human Heart 
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Background: The right ventricular apex (RVA) has been the standard cardiac pacing lead 
implantation site for decades; but recently it has been shown via echocardiography, that 
pacing from this location can induce both ventricular dyssynchrony and deleterious ventricular 
remodeling.  With advances in magnetic resonance imaging (MRI), such as myocardial 
tagging, it is now possible to study regional myocardial deformation and transmural cardiac 
strain.  However, the clinical use of MRI in the assessment of ventricular function during 
cardiac pacing is nonexistent: as having an implanted pacing system is considered as a 
contraindication for cardiac MR (CMR).  Here we have employed MR imaging to visualize 
RVA pacing induced dyssynchrony in an isolated human heart.  
 
Methods and Results: A human donor heart deemed non-viable for transplantation, was 
reanimated using an MR compatible, four-chamber working perfusion system. The heart was 
imaged using a 1.5 tesla MR scanner while being paced at 80 beats/minute from the RVA via 
an epicardial pacing lead. Both four-chamber and tagged short-axis cines were acquired. The 
activation patterns of the LV during pacing demonstrated intraventricular dyssynchrony; as 
the LV mechanical activation proceeded from the septum and anterior wall to the lateral wall, 
with the posterior wall being activated the last.  Likewise, interventricular dyssynchrony was 
demonstrated from the four-chamber cine as the time difference between the peak LV and RV 
free wall motion was 180 ms. Pacing induced dyssynchrony can be clearly seen in the 
supplemental videos. 
 
Conclusions: This unique MRI characterization of RVA pacing induced dyssynchrony within 
an isolated human heart further emphasizes the value of more physiological pacing. 
 
GADD45γ is a Novel Downstream Target of MyoD and Negatively 
Regulates Survival and Self-Renewal of Muscle Stem Cells. 
 
Christopher Tastad, Hiroyuki Hirai, Atsushi Asakura 
 
Stem Cell Institute, Paul and Sheila Wellstone Muscular Dystrophy Center, Department of 
Neurology, University of Minnesota Medical School. Minneapolis, MN, USA, 55455 
 
MyoD is a skeletal muscle-specific transcription factor that plays essential roles in muscle 
stem cell (muscle satellite cells) differentiation and regeneration. Satellite cells derived from 
mice lacking the MyoD gene display significantly delayed myogenic differentiation, compared 
to wild-type satellite cells. To understand molecular mechanisms for differentiation of satellite 
cells by MyoD, we investigated the pathways regulated by MyoD. We noticed that GADD45γ 
(growth arrest and DNA-damage-inducible protein 45 gamma) is a direct MyoD downstream 
gene. GADD45γ has been shown to play an active role in DNA demethylation process. 
Methylation is known to be regulating transcriptional activities and has also been found to be 
involved in muscle-specific gene regulation. Our preliminary results demonstrate that 
GADD45γ was highly expressed in wild-type but not in MyoD-/- satellite cells. Over expression 
of GADD45γ increased myogenic differentiation of wild-type satellite cells and MyoD-/- satellite 
cells. In addition, over expression of GADD45γ in MyoD-/- satellite cells resulted in increased 
cell death. These findings provide valuable insights into mechanisms by which MyoD 
deficiency impairs the role of muscle stem cells in transition from primitive stem cells to 
muscle precursor cells and, thus MyoD may negatively regulate self-renewal of muscle stem 
cells. GADD45γ is the effecter downstream target of MyoD and executes processes of cell 
differentiation and apoptotic cell death through DNA demethylation. 
Structural Dynamics of Cardiac Calcium Regulation 
 
Kurt D. Torgersen, Christine B. Karim, Edmund Howard, & David D. Thomas 
 
Department of Biochemistry, University of Minnesota, Minneapolis, MN, USA 
 
We are using solid-phase peptide synthesis (SPPS), site-directed spin labeling, and 
electron paramagnetic resonance (EPR) to investigate the structural dynamics and protein 
interactions of cardiac calcium regulation.  SPPS has the unique advantage of incorporating 
the amino acid spin label TOAC into the backbone of peptides, which allows direct detection 
of PLB backbone dynamics.  We used this system to measure PLB cytoplasmic domain 
dynamics as a function of S16 phosphorylation and interaction with SERCA.  EPR shows that 
the cytoplasmic domain of PLB exists in a dynamic equilibrium between an ordered (T) state 
and a dynamically disordered (R) state.  Phosphorylation induces an order-to-disorder 
(T-to-R) transition in the cytoplasmic domain of isolated PLB, but induces the opposite effect 
on SERCA-bound PLB, showing that phosphorylated PLB remains bound to active 
SERCA 1.  Based on this and other data, we hypothesize that phosphorylation-dependent 
inhibition relief is dependent on the vertical position of PLB in the lipid bilayer.  We are testing 
this model by measuring the accessibility of TOAC-labeled PLB to paramagnetic relaxation 
enhancers in the lipid bilayer and aqueous phase as a function of SERCA binding and S16 
phosphorylation. 
We used DEER (double electron-electron resonance, a pulsed EPR technique) in 
conjunction with NMR, to solve the structure of the PLB pentamer in lipid bilayers.  Both EPR 
and NMR data show that the PLB pentamer adopts primarily a pinwheel conformation, in 
which the cytoplasmic domains flare outward and interact with the bilayer surface 2.   
We spin-labeled SERCA at 
Cys674 in the P-domain and used 
DEER to measure distances to 
selected sites on the PLB monomer, 
to determine the structure of the 
SERCA-PLB complex in both 
inhibitory and activating states.  The 
distance distribution suggests that 
PLB binds to SERCA in both the R 
and T states (see figure).   
This work was supported by 
NIH (GM27906, RR22362), AHA 
(0615710Z, 0815632G), and the 
Minnesota Supercomputing Institute. 
1. Karim, C. B., Zhang, Z., Howard, 
E. C., Torgersen, K. D. & 
Thomas, D. D. (2006). Phosphorylation-dependent Conformational Switch in Spin-labeled 
Phospholamban Bound to SERCA. J Mol Biol 358, 1032-40. 
2. Traaseth, N. J., Verardi, R., Torgersen, K. D., Karim, C. B., Thomas, D. D. & Veglia, G. (2007). 
Spectroscopic validation of the pentameric structure of phospholamban. Proc Natl Acad Sci U 
S A 104, 14676-81. 
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Prevention of dilated cardiomyopathy by chronic infusion of the 
membrane sealant Poloxamer 188 in canines with muscular dystrophy 
 
DeWayne Townsend1, Immanuel Turner2, Joshua Martindale1 ,Joseph Kornegay3 and Joseph 
Metzger1.  
 
1Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN, 
USA 55455 2Department of Surgery, Duke University, Durham, NC, USA 27710 3Department 
of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA 
27599. 
 
Heart disease is rapidly emerging as a central component of the clinical management of 
patients with Duchenne Muscular Dystrophy (DMD). Previous studies have shown that acute 
intravascular administration of the chemical-based membrane sealant Poloxamer 188 (P188) 
can improve cardiac performance in a mouse model of DMD.  The long-term effects of P188, 
however, have not been tested in any DMD model.  To address this, we used Golden 
Retriever muscular dystrophy (GRMD) animals that have markedly greater cardiomyopathy at 
baseline than dystrophic mice.  We instrumented GRMD animals for continuous intravascular 
infusion of P188 (60 mg/kg/hr) or saline (control) for 60 days.  Prior to treatment, the 
dystrophic dogs had an end-diastolic volume (EDV) of 33±5 ml (n=7). In the chronic saline 
delivery group EDV dilated to 49±6 ml (n=4). In marked contrast, treatment with P188 
prevented this change in ventricular dimension (EDV 32±4 ml, n=3, P<0.05). In addition, 
chronic infusion of P188 significantly improved diastolic function in GRMD animals (Tau: pre-
treatment 25.9±0.8 msec vs. 18.9±0.7 msec post treatment n=4, P<0.05). Saline delivery did 
not alter diastolic parameters. These results provide the first evidence that chronic infusion of 
membrane sealant P188 can effectively block emergent LV dilation in a large animal with 
muscular dystrophy.  
 
This work is supported by NIH-HL086790, MDA 68419, and Foundation to Eradicate 
Duchenne. 
Ca2+-ATPase Drives a Topological Rearrangement in the Transmembrane 
Domain of Phospholamban as Measured by Solid-State NMR 
Spectroscopy 
 
Nathaniel J Traaseth, Raffaello Verardi, Lei Shi, Martin Gustavsson, and Gianluigi Veglia 
 
Calcium cycling in muscle cells drives the relaxation and contraction of both skeletal and 
heart tissue. The sarcoplasmic reticulum (SR) Ca2+-ATPase is central in the relaxation of the 
heart, accounting for ~70% of calcium sequestration. Phospholamban (PLN) is a small 
integral membrane protein regulator of Ca2+-ATPase. Its inhibition of the enzyme is shown in 
calcium dependent activity curves, resulting in decreased ATPase affinity for Ca2+. While 
there have been several successful attempts to gain structural knowledge of the complex 
between PLN and Ca2+-ATPase, no high-resolution structure exists. 
 
One important feature that differentiates membrane proteins from soluble ones is topology. 
This is the specific entanglement between the membrane protein and the lipid bilayer. Probing 
the orientation of the protein has been best achieved using oriented solid-state NMR 
experiments such as PISEMA. These experiments correlate an anisotropic chemical shift 
(15N) with a dipolar coupling (1H-15N), allowing for the resolution of backbone restraints with 
respect to the lipid bilayer normal.  
 
To investigate whether topology plays a role in this membrane protein complex, we 
reconstituted PLN (using 15N labels) in the presence and absence of Ca2+-ATPase (purified 
from rabbit skeletal muscle) into mechanically oriented lipid bilayers. Our results 
unambiguously show that PLN’s topology is substantially altered upon binding the ATPase. 
Specifically, we see the membrane embedded helix (residues 31-52) changes its tilt angle 
with respect to the bilayer normal from ~23° in the absence of the enzyme to ~40° in its 
presence. This substantial topology rearrangement might be a necessary attribute of PLN 
regulation and potentially a central difference between an active and inactive PLN bound 
state to Ca2+-ATPase. 
Improvement of muscular dystrophy phenotypes through an increase in 
vasculature in mdx mice 
 
Mayank Verma, Hiroyuki Hirai, Yoko Asakura, Atsushi Asakura 
 
Stem Cell institute, Paul & Sheila Wellstone Muscular Dystrophy Center, Department of 
Neurology, University of Minnesota Medical School, Minneapolis, MN 
 
Duchhene Muscular Dystrophy (DMD) is an X-linked recessive genetic disease in which the 
gene coding for the protein dystrophin is missing. Recent work demonstrates that the lack of 
dystrophin has been linked to vascular insufficiency. Consequently, the decreased circulation 
may induce a state of ischemia increasing the muscular dystrophy pathogenesis. For an 
effective form of therapy of DMD, both the muscle and the vasculature need to be repaired. 
For this reason, mdx mice with increased vasculature were created by crossing them with Flt1 
gene knockout mice. mdx mice are an animal homologue for DMD. Flt1 is a decoy receptor 
for vascular endothelial growth factor (VEGF) and therefore Flt-1+/- mice display increased 
vascular density. Interestingly, the mdx:Flt1+/- mice with increased angiogenesis display an 
improved muscle histology compared to the mdx mice, including decreased fibrosis, 
calcification and membrane permeability. Functionally, mdx:Flt1+/- mice are also shown to 
have a slightly increase in muscle force production, compared to the mdx mice. 
Consequently, mdx:utrophin-/-:Flt1+/- mice display higher survival rates compared to 
mdx:utrophin-/- mice which show more severe muscle phenotypes than mdx mice and typically 
die within 5 months. These data strongly suggest that increasing the vasculature in DMD may 
be able to ameliorate the histological and functional phenotypes associated with this disease. 
 
Designer Calcium Buffers for Enhancing Contractile and Relaxation 
Performance of Normal and Failing Adult Cardiac Myocytes 
 
Wang Wang1, Erik Arden1, Terri Edwards2, Todd J. Herron2, Eric Devaney2, Immanuel 
Turner2, Jonathan Davis3, James Potter4, Joseph Metzger1,2. 
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Michigan, Ann Arbor, Michigan 48109; 3: Department of Physiology and Cell Biology, Ohio 
State University, Columbus, Ohio 43210; 4: Department of Molecular and Cellular 
Pharmacology, University of Miami Miller School of Medicine, Miami, Florida 33136 
 
The cytosolic calcium (Ca2+) binding protein parvalbumin (Parv) is a unique delayed Ca2+ 
buffer that accelerates cardiac relaxation at base line and during pathophysiological 
challenges. Application of Parv in diastolic heart failure is limited by Parv’s inhibition of 
contractility due to partial Ca2+ buffering during systole. Here we show that targeted genetic 
engineering of the EF hand metal binding sites of Parv produces Parv mutants with altered 
Ca2+ buffering capacities. Through adenovirus-mediated acute gene transfer in adult cardiac 
myocytes, the Parv mutants increased myocytes relaxation speed according to their metal 
binding properties. Surprisingly, in distinction from the wild type Parv and other Parv mutants, 
the Parv D51A/E101Q/F102W (ParvDEF), which has lowered Ca2+ binding affinity and 
increased Mg2+ binding affinity, not only significantly accelerated relaxation but also enhanced 
contractility of myocytes. ParvDEF buffered diastolic Ca2+ to speed up cell relaxation, while 
preserving systolic Ca2+ release and sarcoplasmic reticulum Ca2+ content. ParvDEF 
enhanced contractility by influencing myofilament Ca2+ binding, since a troponin C mutant 
(L29Q) blocked ParvDEF’s effect. In a rabbit model of heart failure, ParvDEF rescued the 
impaired contractility and relaxation of cardiac myocytes. Therefore, ParvDEF specifically 
buffers diastolic Ca2+ to speed up relaxation and interacts with myofilaments to enhance 
contractility in normal and diseased myocytes. The positive lusitropic and inotropic effects of 
ParvDEF make this designer Ca2+ buffer a promising candidate for the treatment of cardiac 
dysfunction. 
 
Gene transfer of engineered cardiac troponin C for modulation of 
myofilament Ca2+ sensitivity 
 
Lin Yang, Jen Davis and Joseph M. Metzger 
 
Department of Integrative Biology and Physiology, 4-240 NHH 
 
Cardiac troponin C (cTnC) is a myofilament Ca2+ sensor responsible for initiating striated 
muscle contraction and relaxation in response to cytosolic Ca2+ fluctuations. Modification of 
the myofilament Ca2+ sensitivity thus holds tremendous therapeutic promise for heart 
diseases like congestive heart failure and inherited cardiomyopathy (CM). We recently 
studied two cTnC mutants, M47A and E40A as Ca2+ sensitizer or desensitizer and for 
modulating sarcomere contraction in adult rat cardiac myocytes via adenovirus-mediated 
gene transfer. M47A cTnC significantly increased myofilament Ca2+ sensitivity and maximally 
activated tension as well as significantly slowed sarcomere relaxation and Ca2+ transient 
decay. By contrast, E40A cTnC decreased myofilament Ca2+ sensitivity and hastened 
relaxation time in intact cardiac myocytes. Based on these in vitro data, on-going studies 
detailed here will focus on exploring physiological roles and therapeutic effects of the two 
cTnC mutants in mouse heart. The M47A and E40A will be respectively delivered to 
myocardium of ischemic heart failure and the R193H cTnI transgenic mouse models. New 
AAV serotypes will be used to realize effective myocardial gene transfer and optimized 
regulation elements will be integrally applied for stable transgene expression. The left 
ventricle (LV) function will be followed by measurement of dP/dt values and haemodynamics 
by use of the Millar catheter. Echocardiography will be employed to record the indices 
including ejection fraction percentage and internal diastolic diameter of LV. All these in vivo 
data will provide the further information on direct physiological effects of M47A and E40A in 
diseased mouse heart. Collectively, gene transfer of designer cTnC Ca2+ sensors into in vitro 
and in vivo cardiac models creates great opportunity for defining their physiological roles in 
modulating myofilament contraction and exploring their therapeutic application for heart 
disease. 
 
